Gene editing · Gene editing · developed by Tessera Therapeutics
TSRA-196 is an in-vivo genome editing product formulated in lipid nanoparticles for intravenous infusion. It is being studied in patients with alpha-1 antitrypsin deficiency (AATD).
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07227207 | Phase 1/2 | Alpha-1 Antitrypsin Deficiency (AATD) | Recruiting | HLSQ |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Alpha-1 Antitrypsin Deficiency (AATD)
Updated Oct 18, 2026. Something wrong or missing? Report it on the HLSQ page.
See HLSQ's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
HLSQ catalysts and pipeline →